NECTIN4 and neoplasm: The fact that in 2019, the American FDA (Food and Drug Administration) approved the use of a cancer drug conjugate with a monoclonal antibody directed against nectin-4 in the treatment of metastatic urothelial cancer opens up possibilities for its potential application in different neoplasms [15].